ライフサイエンスコーパス: desmoglein

1 egulation of KLK5 and abnormal expression of desmoglein 1 (DSG1) and filaggrin, but not PAR2 were ide

2 that autoantibodies against desmoglein 3 and desmoglein 1 (Dsg1) are relevant in the pathogenesis of

3 ated by pathogenic, predominantly IgG4, anti-desmoglein 1 (Dsg1) autoantibodies and is endemic in Lim

4 us (PF), is characterized by pathogenic anti-desmoglein 1 (DSG1) autoantibodies.

5 higus foliaceus (PF), autoantibodies against desmoglein 1 (Dsg1) cause blisters.

6 G4 autoantibody response to the self-antigen desmoglein 1 (Dsg1) cross-reacts with the LJM11 sand fly

7 Desmoglein 1 (Dsg1) is a desmosomal cadherin that is ess

8 wasting (SAM) syndrome, caused by biallelic desmoglein 1 (DSG1) mutations, exhibit skin lesions remi

9 ecular specificity to cleave mouse and human desmoglein 1 (Dsg1) once after glutamic acid residue 381

10 istering disease caused by autoantibodies to desmoglein 1 (Dsg1) that cause loss of epidermal cell ad

11 fferentiation-associated proteins, including desmoglein 1 (Dsg1), desmocollin 1 (Dsc1), and keratins

12 caused by pathogenic IgG4 autoantibodies to desmoglein 1 (DSG1).

13 ed by pathogenic IgG4 autoantibodies against desmoglein 1 (Dsg1).

14 leavage of the desmosomal cadherin component desmoglein 1 (Dsg1).

15 ted between extracellular domains 3 and 4 of desmoglein 1 (Dsg1).

16 he cutaneous epithelium, and discovered that desmoglein 1 and 2 expression correlated with the state

17 ponents, including desmoplakin, plakoglobin, desmoglein 1 and 2, and desmocollin 1a and 2a.

18 ning of other desmosomal proteins, including desmoglein 1 and 2, plakophilin 2, and plakoglobin.

19 aggrin processing and delayed degradation of desmoglein 1 and corneodesmosin.

20 newborn animals with decreased expression of desmoglein 1 and corneodesmosin.

21 hs in understanding the interactions between desmoglein 1 and plakogloben in staphylococcal-mediated

22 et was coimmunoprecipitated with E-cadherin, Desmoglein 1 and Plakoglobin, suggesting that they form

23 eads to decreased cell surface expression of desmoglein 1 and re-localization of its C terminus diffu

24 is characterized by autoantibody binding to desmoglein 1 and/or 3 (dsg1/dsg3).

25 As tissue damage is mediated by anti-desmoglein 1 antibodies, an initial T cell response is a

26 Collectively, our results identify desmoglein 1 as a novel caspase and metalloproteinase su

27 uring keratinocyte apoptosis and also reveal desmoglein 1 as a previously unrecognized regulator of a

28 A change in conformation of desmoglein 1 by calcium depletion was shown, with immuno

29 Depletion of calcium from desmoglein 1 completely inhibited its cleavage by exfoli

30 hat UV-induced caspase cleavage of the human desmoglein 1 cytoplasmic tail results in distinct 17- an

31 In contrast, desmoglein 1 defined more differentiated cell population

32 with an increase in corneodesmosomes and in desmoglein 1 expression.

33 cognized syndrome caused by mutations in the desmoglein 1 gene (DSG1).

34 l, short hairpin RNA-mediated suppression of desmoglein 1 in differentiated keratinocytes protected c

35 , suggesting that the proper conformation of desmoglein 1 is critical for its cleavage.

36 l that a 276-residue DSCR construct of human desmoglein 1 is intrinsically disordered and forms an in

37 The desmoglein 1 membrane proximal region also interacts wit

38 Exfoliative toxin cannot cleave desmoglein 1 pretreated at 56 degrees C or higher or at

39 specificity of exfoliative toxin cleavage of desmoglein 1 resides not only in simple amino acid seque

40 Complementary DNA was isolated from 17 desmoglein 1 specific T cell clones generated from pemph

41 Because cleavage occurs in an area of desmoglein 1 stabilized by calcium, we determined if the

42 th HGF-expressing adenovirus, E-cadherin and Desmoglein 1 were decreased in melanocytes, WM164 and WM

43 spase-3 as the preferred enzyme that cleaves desmoglein 1 within its unique repeating unit domain at

44 directed against desmoglein 3 (Dsg3) and/or desmoglein 1(Dsg1).

45 Dsg1 (desmoglein 1) is a member of the cadherin family of Ca(2

46 desmoglein 4 shares 41% identity with human desmoglein 1, 37% with human desmoglein 2, and 50% with

47 circulating autoantibodies directed against desmoglein 1, a 160 kDa transmembrane desmosomal molecul

48 ion relied largely upon the up-regulation of desmoglein 1, a desmosomal cadherin that maintains the i

49 Western blotting revealed degradation of desmoglein 1, a key corneodesmosome structural protein,

50 DSG1 encodes desmoglein 1, a major constituent of desmosomes, which c

51 taxis (eotaxin 3, CCL26), barrier molecules (desmoglein 1, DSG1), tissue remodeling (periostin, POSTN

52 highly structured calcium-binding domain of desmoglein 1, resulting in loss of its function.

53 ratinocytes by downregulating E-cadherin and Desmoglein 1, therefore frees melanoma cells from the co

54 WM35, expressed normal level E-cadherin and Desmoglein 1, whereas most melanomas (18 out of 20) expr

55 s foliaceus (PF) possess pathogenic IgG anti-desmoglein 1-(Dsg1) autoantibodies.

56 of junctional integrity through cleavage of desmoglein 1.

57 lysis) and pathogenic autoantibodies against desmoglein 1.

58 ease characterized by autoantibodies against desmoglein 1.

59 mes (CD) as well as CD constituent proteins, desmoglein 1.

60 ssed no E-cadherin and significantly reduced Desmoglein 1.

61 s in the desmosomal proteins desmoplakin and desmoglein 1.

62 CE constituents, including downregulation of desmoglein 1.

63 Some undegraded desmoglein 1/desmocollin 1 redistribute uniformly into c

64 No significant changes in the expression of desmogleins 1 and 2 were detected.

65 creased the protein levels of E-cadherin and desmogleins 1 and 3 by 300, 180, and 40%, respectively.

66 Specific staining of KC for E-cadherin and desmogleins 1 and 3 increased by 235, 228, and 148%, res

67 human desmoglein cDNA sharing homology with desmogleins 1, 2, 3 and we name this desmoglein 4.

68 ression patterns of the desmoglein isotypes, desmogleins 1, 2, and 3 in the cutaneous epithelium, and

69 ein isoforms have been characterized, namely desmogleins 1, 2, and 3 that are expressed in a tissue-

70 us epithelia there are two major isoforms of desmoglein, 1 and 3, with different distributions in epi

71 protease activity, resulting in accelerated desmoglein-1 (DSG-1)/corneodesmosome degradation.

72 y severe skin blistering and pathogenic anti-desmoglein-1 (Dsg1) autoantibodies.

73 Desmoglein-1 (DSG1), a desmosomal protein, maintains the

74 The desmosomal cadherin, desmoglein-1 (DSG1), promotes keratinocyte differentiati

75 ies against the desmosomal core glycoprotein desmoglein-1 (Dsg1).

76 ntibodies against a desmosomal glycoprotein, desmoglein-1 (Dsg1).

77 multiple markers of differentiation (such as desmoglein-1 [Dsg1], keratin-1, and loricrin) and abroga

78 We produced recombinant desmoglein-1 and desmoglein-3, and used them in highly s

79 antibody capable of cross-reacting with both desmoglein-1 and desmoglein-3.

80 to S. aureus showed enhanced degradation of desmoglein-1 and filaggrin, whereas small interfering RN

81 EcpA was shown to degrade desmoglein-1 and LL-37 in vitro, disrupt the physical ba

82 st, the major pathogenic antibody recognizes desmoglein-1 and mediates cutaneous disease only.

83 linked immunosorbent assay using recombinant desmoglein-1 and standardized the assay to enable compar

84 In this study we have searched for anti-desmoglein-1 antibodies in sera from parasitic (leishman

85 antigenic peptide candidates triggering anti-Desmoglein-1 autoantibodies.

86 orbed in a concentration-dependent manner by desmoglein-1 but not desmoglein-3.

87 ase in corneodesmosome density and increased desmoglein-1 content, with a decline in serine protease

88 Also antibodies to desmoglein-1 could be absorbed in a concentration-depend

89 A specific and sensitive desmoglein-1 ELISA detected antibodies in 34 of 41 oncho

90 barrier function in association with loss of desmoglein-1 expression and has a regulatory role in rep

91 We previously detected IgG antibodies to desmoglein-1 in 97% of patients, but also in 55% of norm

92 PF), autoantibodies against desmoglein-3 and desmoglein-1 induce epidermal cell detachment (acantholy

93 In contrast, beta-catenin binds to desmoglein-1 more weakly than does plakoglobin.

94 Full affinity binding of desmoglein-1 requires sequences C-terminal to the region

95 ), filaggrin, E-cadherin, claudin, occludin, desmoglein-1 was found, independent of CS therapy.

96 paired barrier function (mediated by loss of desmoglein-1), increased production and/or activity of t

97 mosomal junction proteins corneodesmosin and desmoglein-1, was down-regulated by histamine.

98 In PF, desmoglein-1-specific autoantibodies induce blistering.

99 athogenic antibodies to the EC1-2 domains of desmoglein-1.

100 mao Verde differ in IgG subclass response to desmoglein-1.

101 oped world, is mediated by IgG antibodies to desmoglein-1.

102 associated with acquisition of antibodies to desmoglein-1.

103 -dependent manner by desmoglein-3 but not by desmoglein-1.

104 The accumulated levels of desmoglein 2 (Dsg2) and desmocollin 2 increased 1.7-2.0-

105 Ad14p1), use the epithelial junction protein desmoglein 2 (DSG2) as a receptor for infection.

106 t a group of human adenoviruses (HAdVs) uses desmoglein 2 (DSG2) as a receptor for infection.

107 Recently, we identified desmoglein 2 (DSG2) as the main receptor for a group of

108 n with loss of desmosomal junctional protein desmoglein 2 (DSG2) is a hallmark in the pathogenesis of

109 We recently discovered that desmoglein 2 (DSG2) is a receptor for human adenovirus s

110 The desmosomal cadherin desmoglein 2 (Dsg2) localizes to the intercalated disc c

111 ere enriched with the C-terminal fragment of desmoglein 2 (Dsg2), a desmosomal cadherin often overexp

112 moplakin, plakoglobin, plakophilin 2 (PKP2), desmoglein 2 (DSG2), and desmocollin 2 (DSC2), respectiv

113 in accumulation of the desmosomal cadherin, desmoglein 2 (Dsg2), at cell-cell interfaces accompanied

114 the entire ectodomain of desmosomal cadherin desmoglein 2 (Dsg2), using a combination of small-angle

115 ich binds to the epithelial junction protein desmoglein 2 (DSG2).

116 eric HAd type 3 fibre knob (HAd3K) and human desmoglein 2 (DSG2).

117 and another Alzheimer's disease risk factor, desmoglein 2 (DSG2).

118 sm underlying cAMP-mediated strengthening of desmoglein 2 binding was dependent on expression of the

119 Desmoglein 2 gene (DSG2) mutations cause arrhythmogenic

120 Desmoglein 2 modulates extracellular vesicle release fro

121 Desmoglein 2 was highly expressed by the least different

122 (JUP), Desmoplakin (DSP), Plakophilin 2, and Desmoglein 2), have been identified in patients with ARV

123 tity with human desmoglein 1, 37% with human desmoglein 2, and 50% with human desmoglein 3.

124 eins which bind a critical junction protein, desmoglein 2, triggering the transient and specific open

125 teractions along cell junctions and the mean desmoglein 2-mediated binding forces, whereas N-cadherin

126 e collected at different disease stages from desmoglein 2-mutant mice, a well characterized AC model.

127 In desmoglein 2-mutant mice, cardiomyocyte diameters are no

128 Enhanced desmoglein 2-positive contacts and increased junction le

129 nergic signaling enhances both the number of desmoglein 2-specific interactions along cell junctions

130 en HAdV-D26/48 fiber-knob with CD46, or with Desmoglein 2.

131 (CAR) (Ad2 and Ad5) and the CD46 (Ad35) and desmoglein-2 (Ad7) viral receptors all induce the cGAS/S

132 We have identified desmoglein-2 (DSG-2) as the primary high-affinity recept

133 nd to IEC monolayers and induced cleavage of desmoglein-2 (DSG-2) but not E-cadherin, leading to disr

134 (42%), including desmoplakin (DSP) (n = 6), desmoglein-2 (DSG2) (n = 5), plakophilin-4 (PKP4) (n = 1

135 he palmitoylation of the desmosomal cadherin desmoglein-2 (Dsg2) and characterized the role that palm

136 of transmembrane desmosomal cadherins termed desmoglein-2 (Dsg2) and desmocollin-2 (Dsc2) that affili

137 Desmocollin-2 (Dsc2) and desmoglein-2 (Dsg2) are transmembrane cell adhesion prot

138 Desmoglein-2 (Dsg2) is a desmosomal cadherin that is abe

139 of the other intestinal desmosomal cadherin, desmoglein-2 (Dsg2) that pairs with Dsc2, results in dec

140 akin (n=44; 39%), plakophilin-2 (n=38; 34%), desmoglein-2 (n=30; 26%), and desmocollin-2 (n=1; 1%), w

141 model of ACM (homozygous knock-in of mutant desmoglein-2 [Dsg2(mut/mut)]) that recapitulates the car

142 xclusively express the desmosomal cadherins, Desmoglein-2 and Desmocollin-2 (Dsc2) that contribute to

143 We show that the desmosomal proteins desmoglein-2 and desmocollin-3, the focal adhesion prote

144 ated mostly with variants in desmoplakin and desmoglein-2 genes.

145 on of chromosome 18 comprising both DSC2 and desmoglein-2 genes.

146 uman intestinal epithelial cells express the desmoglein-2 isoform.

147 ariants in desmosomal genes (desmoplakin and desmoglein-2) were identified in 12/25 of the cohort pre

148 rent high-affinity receptors (CAR, CD46, and desmoglein-2), and the magnitude of the cGAS/STING DNA r

149 C caused by mutations in DSG2, which encodes desmoglein-2, a component of the cardiac desmosome.

150 es in desmosomal proteins, plakophilin-2 and desmoglein-2, which have been reported to cause cardiac

151 ch disrupting known functional components of desmoglein-2.

152 ibodies (IgG) target the desmosomal cadherin desmoglein 3 (Dsg3) and compromise keratinocyte cell-cel

153 ies primarily targeting desmosomal cadherins desmoglein 3 (DSG3) and DSG1, leading to loss of keratin

154 toantibodies to desmosomal adhesion proteins desmoglein 3 (Dsg3) and Dsg1.

155 es caused by autoantibodies directed against desmoglein 3 (Dsg3) and/or desmoglein 1(Dsg1).

156 PK activation, whereas the signaling of anti-desmoglein 3 (Dsg3) antibody involved JNK and biphasic p

157 Autoantibodies against desmoglein 3 (Dsg3) have also been detected in sera from

158 autoantibody-mediated disease, in which anti-desmoglein 3 (Dsg3) IgG autoantibodies cause life-threat

159 rder and disorder of the desmosomal cadherin desmoglein 3 (Dsg3) in living cells.

160 ge has been described in B cells reacting to desmoglein 3 (Dsg3) in the autoimmune disease pemphigus

161 or downregulation of the desmosomal cadherin desmoglein 3 (DSG3) in the pathogenesis of PV.

162 Detection of desmoglein 3 (DSG3), a metastatic biomarker for head and

163 ies directed against the desmosomal cadherin desmoglein 3 (Dsg3), the major autoantigen in PV, cause

164 Desmoglein 3 (Dsg3), the pemphigus vulgaris antigen, has

165 ibodies to the keratinocyte adhesion protein desmoglein 3 (Dsg3).

166 e caused by autoantibodies (autoAbs) against desmoglein 3 (Dsg3).

167 well established that autoantibodies against desmoglein 3 and desmoglein 1 (Dsg1) are relevant in the

168 the carboxy- terminal cytoplasmic domains of desmoglein 3 are important for targeting it to the desmo

169 a-catenin by 37%, gamma-catenin by 136%, and desmoglein 3 by 300%, whereas pretreatment with 0.25 mm

170 tinocyte cell surface desmocollin 3, but not desmoglein 3 by immunofluorescence, indicating distinct

171 racellular domain of the desmosomal cadherin desmoglein 3 cause potentially fatal blistering of the s

172 Desmoglein 3 chimeric autoantibody receptor T cells (DSG

173 These findings indicate that desmoglein 3 clustering and endocytosis are associated w

174 We found that the expression pattern of desmoglein 3 correlated with different types of keratini

175 Desmoglein 3 deficiency in mice leads to a phenotype cha

176 onse to veltuzumab generally correlated with desmoglein 3 enzyme-linked immunosorbent assay index val

177 fundibulum and in epidermal inclusion cysts, desmoglein 3 expression was limited mainly to the basal

178 , these data showed that the perturbation of desmoglein 3 found in the Dsg3bal-Pas mice resulted in d

179 Antibody blockade of desmoglein 3 function in pemphigus vulgaris patients lea

180 Genetic deficiency of desmoglein 3 in mice mimics autoimmunity to desmoglein 3

181 desmoglein 3 in mice mimics autoimmunity to desmoglein 3 in pemphigus vulgaris, with mucosal-dominan

182 Desmoglein 3 is a transmembrane component of desmosome c

183 the deletion and causing a truncation of the desmoglein 3 polypeptide by 199 amino acids, eliminating

184 generated a myc-tagged truncated Dsg3bal-Pas desmoglein 3 protein and expressed it in keratinocytes.

185 ecause hypomorphic expression of a truncated desmoglein 3 protein led to a spectrum of severe patholo

186 sion of the myc-tagged truncated Dsg3bal-Pas desmoglein 3 protein resulted in a reduction in staining

187 expressing myc-tagged truncated Dsg3bal-Pas desmoglein 3 protein underwent dramatic changes in cell

188 The myc-tagged truncated Dsg3bal-Pas desmoglein 3 protein was found predominantly in the cyto

189 that resulted in expression of a hypomorphic desmoglein 3 protein with a truncation of an extracellul

190 that this region is essential for targeting desmoglein 3 to the desmosome.

191 is issue, we engineered transgenic mice with desmoglein 3 under the control of the involucrin promote

192 3bal-Pas skin, the corresponding protein for desmoglein 3 was completely absent in the oral mucosal e

193 icle, and in cysts arising from these areas, desmoglein 3 was expressed throughout all layers of the

194 Additionally, steady-state levels of desmoglein 3 were decreased and desmosomes were reduced

195 via impaired redistribution of desmoplakin, desmoglein 3, desmocollin 3, and E-cadherin to the plasm

196 pattern that may result from autoimmunity to desmoglein 3, desmocollin 3, or both desmosomal cadherin

197 pathology not observed in mice deficient in desmoglein 3, similar human genetic alterations may also

198 tibodies to the desmosomal adhesion protein, desmoglein 3.

199 with human desmoglein 2, and 50% with human desmoglein 3.

200 order like that observed for the full-length desmoglein 3.

201 proteins, including the desmosomal cadherin, desmoglein 3.

202 those of controls by day 23, as does that of desmoglein 3.

203 are directed against the desmosomal cadherin desmoglein 3.

204 enic antibodies bind the desmosomal cadherin desmoglein-3 (dsg3), causing epidermal cell-cell detachm

205 ies directed against the desmosomal cadherin desmoglein-3 (Dsg3).

206 ies generated target the desmosomal cadherin desmoglein-3 (Dsg3).

207 e disease mediated by autoantibodies against desmoglein-3 (Dsg3).

208 higus foliaceus (PF), autoantibodies against desmoglein-3 and desmoglein-1 induce epidermal cell deta

209 orbed in a concentration-dependent manner by desmoglein-3 but not by desmoglein-1.

210 popolysaccharide, heat-shock cognate 70, and desmoglein-3 compared with DLE+SLE+ and DLE-SLE+ subject

211 We showed that these antibodies to desmoglein-3 could be absorbed in a concentration-depend

212 s shown that affinity-purified antibodies to desmoglein-3 from patients with pemphigus foliaceus and

213 We detected antibodies to desmoglein-3 in 19 of 276 patients with pemphigus foliac

214 to determine the prevalence of antibodies to desmoglein-3 in patients with pemphigus foliaceus and fo

215 g desmoglein-3, epicutaneous applications of desmoglein-3 induced tolerance that is dependent on LCs.

216 Utilizing a desmoglein-3 mouse model (Dsg3(-/-)) or keratin 5-specif

217 liaceus and fogo selvagem have antibodies to desmoglein-3 that may be involved in the pathogenesis of

218 odies against the desmosomal cadherin, DSG3 (desmoglein-3), cause acantholysis.

219 vulgaris the major pathogenic antibody binds desmoglein-3, and mediates mucosal disease.

220 We produced recombinant desmoglein-1 and desmoglein-3, and used them in highly sensitive and spec

221 pontaneously to a physiological skin self-Ag desmoglein-3, epicutaneous applications of desmoglein-3

222 ta4 integrin, collagen XVII, E-cadherin, and desmoglein-3, is strongly reduced, whereas, surprisingly

223 ion-dependent manner by desmoglein-1 but not desmoglein-3.

224 of cross-reacting with both desmoglein-1 and desmoglein-3.

225 Among them, Desmoglein 4 (Dsg4) was down-regulated in Smad4-deleted

226 Mutations in desmoglein 4 (DSG4), a novel member of the desmosomal ca

227 The human desmoglein 4 cDNA (3.6 kb) contains an open reading fram

228 of the exon/intron organization of the human desmoglein 4 gene (DSG4) demonstrates that it is compose

229 RT-PCR on multiple tissue cDNA samples that desmoglein 4 has very specific tissue expression in sali

230 The essential role of desmoglein 4 in skin was established by identifying muta

231 We provide evidence that desmoglein 4 is a key mediator of keratinocyte cell adhe

232 Human desmoglein 4 shares 41% identity with human desmoglein 1

233 The mouse desmoglein 4 transcript contains an open reading frame o

234 We identified a cadherin family member, desmoglein 4, which is expressed in the suprabasal epide

235 gy with desmogleins 1, 2, 3 and we name this desmoglein 4.

236 tissue cDNA we have demonstrated that mouse desmogleins 4, 5, and 6 are all expressed in the epiderm

237 The desmoglein 5 transcript contains an open reading frame o

238 ecursor of 1060 amino acid residues, and the desmoglein 6 transcript contains an open reading frame o

239 herin, N-cadherin, VE-cadherin (cadherin-5), desmoglein, alpha, beta and gamma catenin, p120(ctn) and

240 In contrast, the transmembrane proteins desmoglein and desmocollin are efficiently transported t

241 ar interactions of the desmosomal cadherins, desmoglein and desmocollin, are required for epidermal c

242 s of patients with PV express autoAbs toward desmoglein and non-Dsg targets.

243 ens junctions, desmosomal cadherins - called desmogleins and desmocollins - link intermediate filamen

244 The desmosomal cadherins, comprising the desmogleins and desmocollins, are calcium-dependent tran

245 ansmembrane components of the desmosome, the desmogleins and desmocollins, are members of the cadheri

246 plasmic domains of the desmosomal cadherins, desmogleins and desmocollins.

247 membrane adhesion molecules and comprise the desmogleins and desmocollins.

248 e presence of desmosomal cadherins, known as desmogleins and desmocollins.

249 impairs the trafficking of the desmoplakins, desmoglein, and desmocollin to the cell surface; these p

250 The desmosomal cadherins, desmogleins, and desmocollins mediate strong intercellul

251 at each visit for ELISA measurement of anti-desmoglein antibodies.

252 d squamous epithelia, such as the epidermis, desmogleins are generally expressed in a differentiation

253 which were distinct for scFvs with different desmoglein-binding specificities.

254 terized, at the genetic level, a novel human desmoglein cDNA sharing homology with desmogleins 1, 2,

255 ed and characterized; pemphigus antigens are desmogleins (cell adhesion molecules in desmosomes), and

256 Anti-desmoglein (Dsg) 1 and Dsg3 IgG autoantibodies in pemphi

257 which is also present in adherens junctions, desmoglein (DSG) 1, 2, 4, and corneodesmosin).

258 PV patients develop pathogenic anti-desmoglein (Dsg) 3 +/- 1 and antimitochondrial antibodie

259 ssion profiles of the desmosomal PV antigens desmoglein (Dsg) 3 and 1 but not of the adherens junctio

260 odies against cell surface adhesion proteins desmoglein (Dsg) 3 and Dsg1.

261 Here, we investigated the roles of desmoglein (Dsg) 3 and plakophilins (Pkps) in hyperadhes

262 d at the surface of keratinocytes, primarily desmoglein (Dsg) 3 and, to a lesser extent, Dsg1.

263 The mPV subset exhibits anti-human desmoglein (Dsg) 3 autoantibodies that fail to recognize

264 or (CAAR), consisting of the PV autoantigen, desmoglein (Dsg) 3, fused to CD137-CD3zeta signaling dom

265 dies against the desmosomal adhesion protein desmoglein (Dsg) 3.

266 ease characterized by autoantibodies against desmoglein (Dsg) 3.

267 Here, we observed that non-desmoglein (Dsg) AuAbs in the sera of patients with Dsg1

268 us membranes caused by autoantibodies to the desmoglein (DSG) family proteins DSG3 and DSG1, leading

269 determined the feasibility of using an anti-desmoglein (Dsg) mAb, Px44, to deliver a biologically ac

270 ntrast to integrins and classical cadherins, desmoglein (Dsg) molecules are not known to elicit intra

271 ity of T(H) and T(FH) cell subsets to induce desmoglein (Dsg)-specific autoantibodies by memory B cel

272 ed against two desmosomal adhesion proteins, desmoglein (Dsg)1 and Dsg3 (also known as DG1 and DG3),

273 ases characterized by autoantibodies against desmoglein (Dsg)1 and Dsg3, respectively.

274 ned for desmocollin (DSC)2, occludin (OCLN), desmoglein (DSG)1, tight junction protein 2, and gap jun

275 e levels of the desmosomal adhesion molecule desmoglein (Dsg)3 by reducing its membrane incorporation

276 epletion of the desmosomal adhesion molecule desmoglein (Dsg)3 induced by autoantibodies from patient

277 t is characterized by autoantibodies against desmoglein (Dsg)3, whereas mucosal and skin lesion-produ

278 Desmoglein (Dsg)3-/- (knockout) mice lose hair during te

279 In keratinocytes, several desmoglein (Dsg1-4) and desmocollin (Dsc1-3) isoforms ar

280 ered intercellular attachments are formed by desmogleins (Dsgs) and desmocollins (Dscs), but the natu

281 The desmosomal cadherins, desmogleins (Dsgs) and desmocollins (Dscs), comprise the

282 Desmosomal cadherins, desmogleins (Dsgs) and desmocollins, make up the adhesiv

283 une disease in which antibodies specific for desmogleins (Dsgs) cause loss of keratinocyte cell adhes

284 We conclude that desmoglein expression patterns define compartments of ce

285 cysteine residues are conserved in all four desmoglein family members.

286 cture and function that uniquely defines the desmoglein family of cell adhesion molecules.

287 omolog as well as two additional novel mouse desmoglein genes situated within the mouse cluster.

288 pression of dominant negative E-cadherin and Desmoglein in melanocytes demonstrated that both molecul

289 Until recently, three mouse and three human desmoglein isoforms had been characterized that are expr

290 To date, three human desmoglein isoforms have been characterized, namely desm

291 Here, we examined expression patterns of the desmoglein isotypes, desmogleins 1, 2, and 3 in the cuta

292 e display technologies to isolate human anti-desmoglein monoclonal antibodies from a patient with pem

293 hogenic effects in anti-desmocollin and anti-desmoglein pemphigus, despite their identical clinical p

294 e investigated the roles of both Dsg and non-desmoglein PV antigens.

295 The desmoglein-specific cytoplasmic region (DSCR) is a conse

296 the disease and highlights the relevance of desmoglein-specific versus nondesmoglein autoantibodies,

297 g that the V(L) is less critical to defining desmoglein specificity.

298 decrease in the detergent-insoluble pool of desmoglein suggested a reduced association with the IF c

299 osphorylated Pg remained associated with the desmoglein tail after both short and long term EGFR acti

300 dulated by the molecular interactions of the desmoglein tail and suggests that these novel regulatory